In CRC, both KRAS-wildtype (wt) and KRAS-mutant (mt) groups with TACSTD2-high tumors experienced worse OS, while in pancreatic cancer, this was observed only in patients with KRAS-mt tumors (Supplementary Figure S4A). This evidence concerns the gene TACSTD2 and familial pancreatic carcinoma.